HCM · HUTCHMED (China) Limited American Depositary Shares
View on chartInsiders & Stakes
No transactions found.
Transaction History
No transactions found.
No transactions found.
No transactions found.
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
HUTCHMED US NDA for ORPATHYS-TAGRISSO Combo
HUTCHMED (China) has submitted a US New Drug Application for the ORPATHYS and TAGRISSO combination in lung cancer. This regulatory step is a key milestone for the company's pipeline in the US market. The stock is currently trading below its 52-week high, reflecting ongoing valuation pressures despite this development.
HUTCHMED US NDA for ORPATHYS-TAGRISSO Combo. HUTCHMED (China) has submitted a US New Drug Application for the ORPATHYS and TAGRISSO combination in lung cancer. This regulatory step is a key milestone for the company's pipeline in the US market. The stock is currently trading below its 52-week high, reflecting ongoing valuation pressures despite this development.